One revolutionary product.

One solution for multiple

inflammatory GI conditions.

Acute and chronic diarrhea. Gastrointestinal distress. Oral mucositis. Radiation proctitis. Salient’s proprietary, patent-pending and all-natural product, CASAD™, is being developed to address these issues. By neutralizing cytokines and other inflammatory agents often caused by infectious diseases, chronic conditions, radiation, cancer therapy and toxic pharmaceuticals, we’re working to improve patient health and the odds of primary therapy success.

Find out more »

Salient's Focus

While the treatment of acute and chronic diarrhea remains Salient’s primary focus, CASAD™ has shown signals of efficacy in the treatment of other inflammatory conditions. Our first Phase II clinical trial will be completed in mid-2012.

Houston Technology Center